facebook button Trials
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Solid Tumor or Lymphoma Zai Lab: ZL-1201-001 Zai Lab (Shanghai) Co., Ltd.
Various Indications [Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) MT Group
Non-Small Cell Lung Cancer LEAP-008: Second Line Lenvatinib and Pembrolizumab Merck Sharp & Dohme Corp.
Ovarian Cancer EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib Ellipses Pharma
Multiple Myeloma [Registry] A Multi-Center, Randomized, Pilot Trial to Evaluate the My Hematology Oncocogy Patient Experience (MYHOPE) for Multiple Myelome (MM) Digital Care Network in Patients with MM (MyHOPE) Celgene Corporation
Colon or Rectal Cancer LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash Lutris Pharma Ltd.
Non-Small Cell Lung Cancer Spectum: Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Chemotherapy-Induced Oral Mucositis Chemo Mouthpiece Medical Device Trial Chemo Mouthpiece, LLC
Non-small Cell Lung Cancer D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer AstraZeneca
Hyperkalemia/Chronic Kidney Disease NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa
Non-Small Cell Lung Cancer TROPION-Lung05: DS-1062a in NSCLC with actionable genetic mutations Daiichi Sankyo, Inc.
Non-Small Cell Lung Cancer Second Line Sitravatinib Plus Nivolumab Mirati Therapeutics, Inc.
Solid Tumors [Sample Collection] A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers (SEERPRO) Seer, Inc.
Various Indications [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine
Oropharynx or Oral Cavity Cancer Galera ROMAN: GC4419 for Radiation Induced Oral Mucositis Galera Therapeutics, Inc.
Hematologic Malignancies KPG-818 for Patients with Hematologic Malignancies Kangpu Biopharmaceuticals, Ltd.
Solid Tumors MyTACTIC: Multiple Cohort Solid Tumor Trial Genentech, Inc.
Prostate Cancer KPG-121 in Castration Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd.
Solid Tumors Clovis LODESTAR: Rucaparib in HRD Mutated Solid Tumors Clovis Oncology, Inc.
Non-Small Cell Lung Cancer Zeno: ZN-e4-001 Zeno Pharmaceuticals, Inc.
Various Indications [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC.
Bone Metastasis CBD for Opioid Reduction VerdePharmHealth, LLC
Solid Tumors Merck KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors Merck Sharp & Dohme Corp.
Pancreatic Cancer Ipsen Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel Ipsen
Urothelial Carcinoma Basilea: Derzantinib for Patients with a Mutation in FGFR1-3 Basilea Pharmaceutica
Cutaneous Squamous Cell Carcinoma [Registry] CemiplimAb in Cutaneous Squamous Cell Carcinoma (CASE) Regeneron Pharmaceuticals, Inc.
Pancreatic Cancer Tyme-88-Panc: SM-88 as Third Line Therapy Tyme, Inc.
Ovarian Cancer AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer Aravive, Inc.
Myelodysplatic Syndrome or Acute Myeloid Leukemia [Registry] An Observational Study to Collect and Assess Tissue Samples from Subjects With Documented Hematologic Malignancy (ANSWer) Notable Labs
Advanced or Metastatic Solid Tumors Exelixis: Cabozantinib plus Atezolizumab for Subjects with Locally Advanced or Metastatic Solid Tumors Exelixis